Company profile: ImmunOs Therapeutics
1.1 - Company Overview
Company description
- Provider of next-generation human immunomodulatory therapeutics. The clinical-stage company develops IOS-1002, an immunotherapy targeting multiple immune-suppressive receptors for solid tumors and hematologic malignancies; an HLA-based platform for biologics against cancer and autoimmune diseases; and antibodies blocking specific HLA molecules for autoimmune conditions.
Products and services
- Antibodies for autoimmune diseases: HLA-targeted antibodies that block specific HLA molecules associated with autoimmune diseases including ankylosing spondylitis, lupus, psoriasis, and IBD
- HLA-based technology platform: Proprietary platform utilizing specific HLA molecules to develop biologic therapeutics targeting cancer and autoimmune diseases across innate and adaptive immunity mechanisms
- IOS-1002: Multi-receptor immunotherapy product that targets multiple immune-suppressive receptors to treat solid tumors and hematologic malignancies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ImmunOs Therapeutics
Onyvax
HQ: United Kingdom
Website
- Description: Provider of cancer therapies that harness the immune system’s selective power to seek out and destroy tumor cells, specifically targeting cancer cells to improve effectiveness while minimizing side effects compared to conventional treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onyvax company profile →
ImmuVen
HQ: United States
Website
- Description: Provider of biotherapeutic discovery and drug development for infectious diseases, cancer, and autoimmune disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuVen company profile →
Arcus Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical cancer therapies, focused on discovering, developing, and commercializing novel treatments. Investigational portfolio includes domvanalimab (Fc-silent anti-TIGIT), zimberelimab (anti-PD-1), etrumadenant (dual A2a/A2b antagonist), quemliclustat (CD73 inhibitor), casdatifan (HIF-2⍺ inhibitor for renal cell cancer), and AB598 (Fc-silent anti-CD39).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcus Biosciences company profile →
Argenx
HQ: United States
Website
- Description: Provider of immunology therapies for severe autoimmune diseases and cancer, including efgartigimod, an investigational antibody fragment targeting FcRn for severe autoimmune diseases with pathogenic IgG autoantibodies; ARGX-117, a humanized sweeping antibody inhibiting C2 and downstream complement in IgM-driven diseases; and empasiprubart, a human IgG1 anti-C2 sweeping antibody with enhanced FcRn binding to improve C2 clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argenx company profile →
Ankyra Therapeutics
HQ: United States
Website
- Description: Provider of anchored immunotherapy for cancer treatments as a biotech company developing immunotherapy solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ankyra Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ImmunOs Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ImmunOs Therapeutics
2.2 - Growth funds investing in similar companies to ImmunOs Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ImmunOs Therapeutics
4.2 - Public trading comparable groups for ImmunOs Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →